ORX — Orexo AB Share News
0.000.00%
Last trade - 00:00- SEK850.39m
- SEK471.19m
- SEK26.00m
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens
Brief: Orexo Reports Q1 Loss Of SEK 105.2 Million
Brief: Orexo Calls For Early Redemption Of Outstanding Senior Secured Social Bonds
Sweden's Orexo Q4 net earnings rise on Zubsolv sale
Brief: Orexo Q4 EBIT Loss At SEK 103.2 Mln
Brief: Orexo Q3 Revenue AT SEK 118.7 Mln, Guidance Unchanged
Brief: Orexo US Awarded $8 Mln For OX390 Development Partnership
Brief: Orexo Announces Positive Pharmacokinetic In-Vivo Data For Powder-Based Intranasal Semaglutide Formulation
Brief: Orexo Maintains 2025 Financial Outlook
Brief: Orexo Appoints Friedrich Von Bohlen Und Halbach As Chairman
Brief: Orexo Q1 EBIT SEK -5.2 Million
Brief: Orexo Announces Positive Data For Powder-Based Intranasal Vaccine
Brief: Orexo Sees Positive EBITDA For FY 2025
Brief: Orexo Q4 EBIT SEK -98 Million
Brief: Orexo Converts Future Rights For OX-MPI To Shares In Gesynta Pharma Valued At SEK 19 Mln
Brief: Orexo Announces Positive Topline Data From Clinical Study Of OX640